Plasma center utilization rates and donor traffic trends - directly impacts disposables volume which represents 45-50% of total revenue
Hospital surgical procedure volumes, particularly cardiac and orthopedic surgeries where Cell Saver adoption is highest
New product launch momentum: Vascular Closure Device (VCD) rollout, NexSys PCS upgrades, TEG Manager software adoption
Plasma pricing dynamics and customer inventory destocking cycles at major customers (CSL, Grifols, Takeda)
moderate - Plasma segment exhibits counter-cyclical characteristics as donor traffic increases during economic weakness (unemployment drives plasma donations). Hospital segment is moderately pro-cyclical, tied to elective surgical volumes which decline in recessions but are less discretionary than cosmetic procedures. Overall company revenue showed resilience during 2020 downturn with only 3% decline, recovering to growth by 2021. Healthcare capital equipment spending by hospitals correlates with patient volumes and reimbursement rates.
Rising rates create modest headwinds through two channels: (1) Higher cost of debt refinancing - company carries $375M net debt (1.34x equity) with portions subject to floating rates, adding 50-75 bps interest expense per 100 bps rate increase; (2) Valuation multiple compression as medtech stocks typically trade at premium P/E ratios (20-25x) which contract when risk-free rates rise. However, business fundamentals are largely rate-insensitive as hospitals finance equipment through operating budgets rather than credit-dependent purchases. Limited direct impact on end-market demand.
Plasma industry consolidation risk - top 3 customers (CSL, Grifols, Takeda) represent 40-45% of revenue; customer bankruptcies or vertical integration into device manufacturing could disrupt revenue streams
Regulatory pathway changes - FDA 510(k) process modifications or increased scrutiny on blood safety could delay new product launches or require costly clinical trials; EU MDR implementation added 12-18 month approval timelines
Reimbursement pressure - CMS payment rate cuts for hospital blood management procedures could reduce capital equipment budgets; plasma reimbursement changes in Europe affect customer profitability
value - Stock trades at 9.9x EV/EBITDA vs medtech peer average of 14-16x, offering 30-40% valuation discount despite 20%+ ROE and improving margins. Recent 18.5% pullback (3-month) creates entry point for investors betting on margin expansion story and plasma market recovery. Attracts healthcare specialists focused on recurring revenue models and operational turnarounds. Limited dividend (estimated <1% yield) reduces income investor appeal. 42.7% EPS growth demonstrates emerging growth characteristics, but modest 4% revenue growth keeps momentum investors away.
Trend
-5.1% vs SMA 50 · -10.9% vs SMA 200
Momentum
Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $1.4B $1.3B–$1.4B | — | $4.54 | — | ±0% | High7 |
FY2026(current) | $1.3B $1.3B–$1.3B | ▼ -2.5% | $4.94 | ▲ +8.8% | ±1% | High9 |
FY2027 | $1.4B $1.4B–$1.4B | ▲ +5.7% | $5.22 | ▲ +5.6% | ±1% | High9 |
INSTITUTIONAL OWNERSHIP
HAE News
About
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
HAE◀ | $56.29 | -1.45% | $2.6B | 26.7 | -196.9% | 729.4% | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.96% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -2.85% | — | 38.5 | +341821.7% | -3397.7% | 1500 |